Personalized medicine: Caught between hope, hype and the real world

Clinics

Volumn 67, Issue SUPPLEMENT, 2012, Pages 91-97

  Dammann, Marc ^a   Weber, Frank ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Genomic Medicine; Inherited Endocrine Neoplasia; Tumor Syndromes

Indexed keywords

ADRENAL TUMOR; GENETIC PREDISPOSITION; GENETICS; GENOMICS; HUMAN; MEDICAL RESEARCH; MEDULLARY CARCINOMA; PEDIGREE; PERSONALIZED MEDICINE; PHEOCHROMOCYTOMA; REVIEW; SIPPLE SYNDROME; THYROID TUMOR;

ADRENAL GLAND NEOPLASMS; BIOMEDICAL RESEARCH; CARCINOMA, MEDULLARY; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PEDIGREE; PHEOCHROMOCYTOMA; THYROID NEOPLASMS;

EID: 84863900139     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(Sup01)16     Document Type: Review

References (57)

1. Weber F, Fukino K, Sawada T, Williams N, Sweet K, Brena RM, et al. Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. Br J Cancer. 2005;92(10):1922-6, http://dx.doi.org/10.1038/sj.bjc.6602557.
2. Hou YY, Grabellus F, Weber F, Zhou Y, Tan YS, Li J, et al. Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection. J Gastrointest Surg. 2009;13(9):1583-92, http://dx.doi.org/10.1007/s11605-009-0842-6.
3. Landa I, Montero-Conde C, Malanga D, De Gisi S, Pita G, Leandro-Garcia LJ, et al. Allelic variant at-79 (C. T) in CDKN1B (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels. Endocr Relat Cancer. 2010;17(2):317-28.
4. Weber F, Eng C. Gene-expression profiling in differentiated thyroid cancer: a viable strategy for the practice of genomic medicine? Future Oncol. 2005;1(4):497-510.
5. Niemeier LA, Kuffner Akatsu H, Song C, Carty SE, Hodak SP, Yip L, et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer. Aug 31 [epub ahead of print].
6. Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010;363(2):166-76.
7. Adamzik M, Frey UH, Mohlenkamp S, Scherag A, Waydhas C, Marggraf G, et al. Aquaporin 5 gene promoter: 1364A/C polymorphism associated with 30-day survival in severe sepsis. Anesthesiology. 2011;114(4):912-17.
8. Anney R, Klei L, Pinto D, Regan R, Conroy J, Magalhaes TR, et al. A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet. 2010;19(20):4072-82.
9. McCarthy MI, Hirschhorn JN. Genome-wide association studies: potential next steps on a genetic journey. Hum Mol Genet. 2008;17(R2):R156-65, http://dx.doi.org/10.1093/hmg/ddn289.
10. Dorn GW, 2nd. The genomic architecture of sporadic heart failure. Circ Res. 2011;108(10):1270-83.
11. Park SJ, Jung EH, Ryu RS, Kang HW, Ko JM, Kim HJ, et al. Clinical implementation of whole-genome array CGH as a first-tier test in 5080 pre and postnatal cases. Mol Cytogenet. 2011;4:12.
12. Guttmacher AE, McGuire AL, Ponder B, Stefansson K. Personalized genomic information: preparing for the future of genetic medicine. Nat Rev Genet. 2010;11(2):161-5.
13. Hall WD, Mathews R, Morley KI. Being more realistic about the public health impact of genomic medicine. PLoS Med. 2010;7(10):e1000347, http://dx.doi.org/10.1371/journal.pmed.1000347
14. Feero WG, Guttmacher AE, Collins FS. Genomic medicine: an updated primer. N Engl J Med. 2010;362(21):2001-11, http://dx.doi.org/10.1056/NEJMra0907175.
15. Paynter NP, Chasman DI, Buring JE, Shiffman D, Cook NR, Ridker PM. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med. 2009;150(2):65-72.
16. Colombo S, Rauch A, Rotger M, Fellay J, Martinez R, Fux C, et al. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J Infect Dis. 2008;198(6):864-7, http://dx.doi.org/10.1086/591184.
17. Buchan BW, Peterson JF, Cogbill CH, Anderson DK, Ledford JS, White MN, et al. Evaluation of a Microarray-Based Genotyping Assay for the Rapid Detection of Cytochrome P450 2C19 *2 and *3 Polymorphisms From Whole Blood Using Nanoparticle Probes. Am J Clin Pathol. 2011;136(4):604-8.
18. Frilling A, Weber F, Tecklenborg C, Broelsch CE. Prophylactic thyroidectomy in multiple endocrine neoplasia: the impact of molecular mechanisms of RET proto-oncogene. Langenbecks Arch Surg. 2003;388(1):17-26.
19. Frilling A, Weber F. Prophylactic thyroid surgery. Chirurg. 2006;77(1):6-14, http://dx.doi.org/10.1007/s00104-005-1118-7.
20. Weber F, Eng C. Update on the molecular diagnosis of endocrine tumors: toward-omics-based personalized healthcare? J Clin Endocrinol Metab. 2008;93(4):1097-104, http://dx.doi.org/10.1210/jc.2008-0212.
21. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol. 1999;17(1):380-93.
22. Frilling A, Dralle H, Eng C, Raue F, Broelsch CE. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Surgery. 1995;118(6):1099-103; discussion 1103-4, http://dx.doi.org/10.1016/S0039-6060(05)80120-5
23. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276(19):1575-9.
24. Milos IN, Frank-Raue K, Wohllk N, Maia AL, Pusiol E, Patocs A, et al. Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC. TGG) mutation. Endocr Relat Cancer. 2008;15(4):1035-41, http://dx.doi.org/10.1677/ERC-08-0105.
25. Weber F, Eng C. Editorial: germline variants within RET: clinical utility or scientific playtoy? J Clin Endocrinol Metab. 2005;90(11):6334-6, http://dx.doi.org/10.1210/jc.2005-2030.
26. Tamanaha R, Camacho CP, Pereira AC, da Silva AM, Maciel RM, Cerutti JM. Evaluation of RET polymorphisms in a six-generation family with G533C RET mutation: specific RET variants may modulate age at onset and clinical presentation. Clin Endocrinol (Oxf). 2009;71(1):56-64, http://dx.doi.org/10.1111/j.1365-2265.2008.03491.x.
27. Jiang Q, Ho YY, Hao L, Nichols Berrios C, Chakravarti A. Copy number variants in candidate genes are genetic modifiers of Hirschsprung disease. PLoS One. 2011;6(6):e21219.
28. Erlic Z, Rybicki L, Peczkowska M, Golcher H, Kann PH, Brauckhoff M, et al. Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res. 2009;15(20):6378-85, http://dx.doi.org/10.1158/1078-0432.CCR-09-1237.
29. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer. 2004;11(3):423-36, http://dx.doi.org/10.1677/erc.1.00829.
30. Eng C. Familial papillary thyroid cancer: many syndromes, too many genes? J Clin Endocrinol Metab. 2000;85(5):1755-7, http://dx.doi.org/10.1210/jc.85.5.1755.
31. Eng C. Mendelian genetics of rare-andnot so rare-cancers. Ann NY Acad Sci. 2010;1214:70-82.
32. Eng C. Common alleles of predisposition in endocrine neoplasia. Curr Opin Genet Dev. 2010;20(3):251-6.
33. Tomoda C, Miyauchi A, Uruno T, Takamura Y, Ito Y, Miya A, et al. Cribriform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis-associated colon cancer. World J Surg. 2004;28(9):886-9, http://dx.doi.org/10.1007/s00268-004-7475-4.
34. Muftuoglu M, Oshima J, von Kobbe C, Cheng WH, Leistritz DF, Bohr VA. The clinical characteristics of Werner syndrome: molecular and biochemical diagnosis. Hum Genet. 2008;124(4):369-77, http://dx.doi.org/10.1007/s00439-008-0562-0.
35. Stratakis CA, Courcoutsakis NA, Abati A, Filie A, Doppman JL, Carney JA, et al. Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex). J Clin Endocrinol Metab. 1997;82(7):2037-43, http://dx.doi.org/10.1210/jc.82.7.2037.
36. Snabboon T, Plengpanich W, Saengpanich S, Sirisalipoch S, Keelawat S, Sunthornyothin S, et al. Two common and three novel PDS mutations in Thai patients with Pendred syndrome. J Endocrinol Invest. 2007;30(11):907-13.
37. Malchoff CD, Sarfarazi M, Tendler B, Forouhar F, Whalen G, Malchoff DM. Familial papillary thyroid carcinoma is genetically distinct from familial adenomatous polyposis coli. Thyroid. 1999;9(3):247-52, http://dx.doi.org/10.1089/thy.1999.9.247.
38. Hemminki K, Eng C, Chen B. Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab. 2005;90(10):5747-53, http://dx.doi.org/10.1210/jc.2005-0935.
39. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994;86(21):1600-8.
40. Charkes ND. On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds. Thyroid. 2006;16(2):181-6, http://dx.doi.org/10.1089/thy.2006.16.181.
41. Hemminki K, Eng C. Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. J Med Genet. 2004;41(11):801-7, http://dx.doi.org/10.1136/jmg.2004.022731.
42. Khan A, Smellie J, Nutting C, Harrington K, Newbold K. Familial nonmedullary thyroid cancer: a review of the genetics. Thyroid. 2010; 20(7):795-801.
43. Lesueur F, Stark M, Tocco T, Ayadi H, Delisle MJ, Goldgar DE, et al. Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium. J Clin Endocrinol Metab. 1999;84(6):2157-62, http://dx.doi.org/10.1210/jc.84.6.2157.
44. Bignell GR, Canzian F, Shayeghi M, Stark M, Shugart YY, Biggs P, et al. Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet. 1997;61(5):1123-30, http://dx.doi.org/10.1086/301610.
45. Malchoff CD, Sarfarazi M, Tendler B, Forouhar F, Whalen G, Joshi V, et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab. 2000;85(5):1758-64, http://dx.doi.org/10.1210/jc.85.5.1758.
46. McKay JD, Lesueur F, Jonard L, Pastore A, Williamson J, Hoffman L, et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet. 2001;69(2):440-6, http://dx.doi.org/10.1086/321979.
47. Cavaco BM, Batista PF, Sobrinho LG, Leite V. Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis. J Clin Endocrinol Metab. 2008;93(11):4426-30, http://dx.doi.org/10.1210/jc.2008-0449.
48. Cavaco BM, Batista PF, Martins C, Banito A, do Rosario F, Limbert E, et al. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations. Endocr Relat Cancer. 2008;15(1):207-15, http://dx.doi.org/10.1677/ERC-07-0214.
49. Loh KC. Familial nonmedullary thyroid carcinoma: a meta-review of case series. Thyroid. 1997;7(1):107-13, http://dx.doi.org/10.1089/thy.1997.7.107.
50. Burgess JR, Duffield A, Wilkinson SJ, Ware R, Greenaway TM, Percival J, et al. Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid. J Clin Endocrinol Metab. 1997;82(2):345-8, http://dx.doi.org/10.1210/jc.82.2.345.
51. Capezzone M, Marchisotta S, Cantara S, Busonero G, Brilli L, Pazaitou-Panayiotou K, et al. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. Endocr Relat Cancer. 2008;15(4):1075-81, http://dx.doi.org/10.1677/ERC-08-0080.
52. Alsanea O, Wada N, Ain K, Wong M, Taylor K, Ituarte PH, et al. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery. 2000;128(6):1043-50; discussion 50-1, http://dx.doi.org/10.1067/msy.2000.110848
53. Uchino S, Noguchi S, Kawamoto H, Yamashita H, Watanabe S, Shuto S. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg. 2002;26(8):897-902, http://dx.doi.org/10.1007/s00268-002-6615-y.
54. Robenshtok E, Tzvetov G, Grozinsky-Glasberg S, Shraga-Slutzky I, Weinstein R, Lazar L, et al. Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study. Thyroid. 2011;21(1):43-8.
55. Ito Y, Kakudo K, Hirokawa M, Fukushima M, Yabuta T, Tomoda C, et al. Biological behavior and prognosis of familial papillary thyroid carcinoma. Surgery. 2009;145(1):100-5, http://dx.doi.org/10.1016/j.surg.2008.08.004.
56. Bloss CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med. 2011;364(6):524-34.
57. Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer. 2007;7(1):35-45, http://dx.doi.org/10.1038/nrc2037.